Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Travis Johnson, Enze Liu, Ke Yang, Parvathi Sudha, Vivek S. Chopra, Faiza Zafar, Rafat Abonour, Brian A. Walker

Blood (2024) 144 (Supplement 1): 4657.

https://doi.org/10.1182/blood-2024-211489

Published: 2024

Journal Articles

Real-World Progression-Free Survival and Treatment Patterns for t(11;14) Positive Patients with Multiple Myeloma with at Least 2 Prior Lines of Treatment

Allicia Girvan, Daniel Martins, Junhua Yu, Sophia Ng, Rajesh Kamalakar, Faiza Zafar, Seema Tulsian, Robert F. Cornell, Mohamed Samir

Blood (2023) 142 (Supplement 1): 6667.

https://doi.org/10.1182/blood-2023-173446

Published: 2023

Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Blood (2018) 132 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2018-99-111920

Published: 2018

Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Blood (2018) 132 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2018-99-111554

Published: 2018

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Jason Tay, MD FRCPC, Ravi Vij, MDMBA, Maxim Norkin, MD, Shaji K Kumar, MD, Tamila L Kindwall-Keller, DO, Jenna S Roberts, PhD, Darrell J White, MD, Robert P Wood, BSc, Sophee E Blanthorn-Hazell, MSc, BSc, Adriana C. Rossi, MDMSc, Sujith Dhanasiri, MSc, Faiza Zafar, MPAS, Kim Newhouse, BSc. , BScN, McCurdy R Arleigh, MD MHA, FRCPC

Blood (2017) 130 (Supplement 1): 2150.

https://doi.org/10.1182/blood.V130.Suppl_1.2150.2150

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Howard R. Terebelo, DO, Rafat Abonour, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Lihua Yue, PhD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 1842.

https://doi.org/10.1182/blood.V130.Suppl_1.1842.1842

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

Robert M. Rifkin, MD, Rafat Abonour, MD, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, Sundar Jagannath, MD, Mohit Narang, MD, Jatin J. Shah, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Amani Kitali, MPH, PMP, Faiza Zafar, BSc, MBBS, Shankar Srinivasan, PhD, James W. Hardin, PhD

Blood (2016) 128 (22): 4489.

https://doi.org/10.1182/blood.V128.22.4489.4489

Published: 2016

Journal Articles

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Adriana C Rossi, MD, Tomer M Mark, MD, MSc, Kevin Wood, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Stanley Goldsmith, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1878.

https://doi.org/10.1182/blood.V122.21.1878.1878

Published: 2013

Journal Articles

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Angelique Boyer, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1954.

https://doi.org/10.1182/blood.V122.21.1954.1954

Published: 2013

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Geoffrey Marano, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Linda Tegnestam, RN, Karen Pekle, NP, David Jayabalan, B.S.M.S, Morton Coleman, MD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD

Blood (2013) 122 (21): 3216.

https://doi.org/10.1182/blood.V122.21.3216.3216

Published: 2013

Journal Articles

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Adriana Rossi, Tomer Mark, David Jayabalan, Paul Christos, Faiza Zafar, Karen Pekle, Roger Pearse, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2013) 121 (11): 1982–1985.

https://doi.org/10.1182/blood-2012-08-448563

Published: 2013

Includes: Supplemental data

Journal Articles

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Manan Shah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, Erlinda A Sacris, RN, June Greenberg, RN, Stephanie Speaker, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2012) 120 (21): 77.

https://doi.org/10.1182/blood.V120.21.77.77

Published: 2012

Journal Articles

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Melissa Rodriguez, Manan Shah, Ryann Quinn, Jessica Campbell, Ramsey Abdullah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 635.

https://doi.org/10.1182/blood.V118.21.635.635

Published: 2011

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 2937.

https://doi.org/10.1182/blood.V118.21.2937.2937

Published: 2011

NARROW

Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Real-World Progression-Free Survival and Treatment Patterns for t(11;14) Positive Patients with Multiple Myeloma with at Least 2 Prior Lines of Treatment

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect ® MM Registry

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only